• Grapiprant is a selective antagonist for

  2021-03-16

  

  Grapiprant () is a selective antagonist for prostaglandin E (PGE) receptor subtype 4 (EP4) identified as a clinical candidate for the treatment of inflammatory pain associated with osteoarthritis (OA). It is currently under development for use in humans and dogs. The projected dosing regimen of grap

• In order to evaluate the in vivo pharmacology

  2021-03-16

  

  In order to evaluate the in vivo pharmacology associated with EP receptor antagonism, we wished to discover antagonists presenting a higher degree of selectivity over the other prostanoid receptors. We also wanted to increase the brain–blood ratio since it is probable that centrally mediated EP agon

• br Conclusions br Declaration of interest

  2021-03-16

  

  Conclusions Declaration of interest Acknowledgements Introduction Uncorrected obesity has been a major health problem and the prevalence of obesity is fast rising reaching an epidemic proportion [[1], [2], [3]]. Ample of clinical and experimental evidence has suggested that obesity leads

• br Acknowledgments This work was supported by a grant

  2021-03-16

  

  Acknowledgments This work was supported by a grant from the National Center for GM Crops (PJ008152) of the Next Generation BioGreen 21 Program funded by the Rural Development Administration, Republic of Korea, to W.T.K. Introduction Ubiquitin (Ub) has been considered as one of the most import

• br Introduction The innate immune system stands the

  2021-03-16

  

  Introduction The innate immune system stands the first line of the defense that protects the host from viral intrusion, depending on pattern recognition receptors (PRRs) and the corresponding pathways [[1], [2], [3], [4]]. The pathogen-associated molecular patterns (PAMPs) of the invading viruses

• br Funding This work was supported by the grants from

  2021-03-16

  

  Funding This work was supported by the grants from MSD, Terumo Life Science Foundation, Takeda Science Foundation, and Japan Diabetes Foundation. Disclosures Acknowledgments The authors thank C. Morimoto (Juntendo University, Tokyo, Japan) and K. Takeda (Immunology Frontier Research Center

• br Acknowledgements This work was supported by grants from A

  2021-03-16

  

  Acknowledgements This work was supported by grants from Agence Nationale de la Recherche (ANR CAPHE) and from Ligue contre le Cancer. We acknowledge the continuous support of CNRS and the University of Strasbourg. We thank the technical assistance of the “Plateforme de Chimie Intégrative de Stras

• br Data deposition The structure factor amplitudes and

  2021-03-16

  

  Data deposition: The structure factor amplitudes and coordinates of mIL34 and the mIL-34:mCSF-1R complex have been deposited in the Protein Data Bank, www.pdb.org, with accession codes 4EXN and 4EXP. Note added in proof The authors would like to inform the readers of two recent articles that are

• ccgs australia These cognitive deficits may suggest that

  2021-03-15

  

  These cognitive deficits may suggest that cognitive therapy and pharmacotherapy for gambling behavior may ultimately wish to consider genotyping as a means of better targeting treatment approaches. If core cognitive deficits are shown consistently in certain subgroups of gamblers based on genotype,

• Prenylation may turn a flavonoid from an agonist to

  2021-03-15

  

  Prenylation may turn a flavonoid from an agonist to an antagonist and improve the selectivity to both ERs depending on the position of the substitution. C-8 prenylation appears to promote antagonism to a larger extent than C-6 in ERα due to steric hindrance against generation of agonistic conformati

• Interestingly several ES cell lines are null

  2021-03-15

  

  Interestingly, several ES cell lines are null for p53, possibly because the EWS-FLI1 chimeric protein can directly and indirectly interfere with p53 activity [38], [39]. The inhibition, loss and/or mutation of p53, one of the most common events in tumorigenesis, results in a decreased oxygen consump

• One possible pitfall of using EPAC activators in

  2021-03-15

  

  One possible pitfall of using EPAC2 activators in the treatment of T2DM is their potential to increase glucagon levels. As discussed previously, although the ability of EPAC2 to increase glucagon expression and production is controversial, several studies show that this protein increases Gcg mRNA le

• p2y receptor The cytoplasmic domain of classical cadherins

  2021-03-15

  

  The cytoplasmic domain of classical cadherins is highly conserved and can interact with different cytosolic proteins. Typically this domain is associated with catenin family members, including p120 catenin, β-catenin, and α-catenin, which form a cadherin-catenin complex (Fig. 1). The catenin family

• br Materials and methods br Results and discussion br

  2021-03-15

  

  Materials and methods Results and discussion Conclusions Data about the ability of non-conventional ligands to operate class-A GPCRs have been accumulating. Specifically, increasing evidence indicates that oxysterols, oxidized derivatives of cholesterol, are involved in many activities that

• Also our data from this study indicate that gestational GC

  2021-03-15

  

  Also, our data from this study indicate that gestational GC exposure altered hematological and hemorheological parameters, however reports exist that altered blood rheological markers are associated with atherosclerosis and CVD (Tzoulaki et al., 2007). Also, the platelet to lymphocyte ratio (PLR) ha

14250 records 668/950 page Previous Next First page 上5页 666667668669670 下5页 Last page